Toggle Nav
My Cart
Search
Advanced Search
Menu
Account
Settings

Technological Advances Enabling Stem Cells Reprogramming

Healthcare Technological Advances Enabling Stem Cells Reprogramming

Technologies Paving New Avenues to Drive Breakthrough Research Toward the Discovery of Next Generation Therapeutics

INDUSTRY
Healthcare
SECTOR
Life Sciences

RELEASE DATE
30-Apr-2019
REGION
Global
DELIVERABLE TYPE
Technology Research

RESEARCH CODE
D89C-01-00-00-00
SKU
HC03169-GL-TR_23095
Yes
SHARE

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03169-GL-TR_23095

Technological Advances Enabling Stem Cells Reprogramming
Published on: 30-Apr-2019 | SKU: HC03169-GL-TR_23095

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Request Sample
Add to Compare
Need more details?
Description

Since the advent of stem cells reprogramming after the discovery of the differentiation factors that allow the creation of human induced pluripotent stem cells, researchers all around the world are strongly committed to develop novel methods to design and build human stem cells.

Indeed, there is an increasing demand for the more efficient production systems and manufacturing methods of stem cells for potential investigation in disease management. This trend is emphatically envisaged to accelerate the development of both regenerative medicine and drug discovery and development.

Moreover, stem cell therapies are acclaimed as the next major advancements in transforming healthcare. Pharmaceutical companies are heavily investing in expanding their cellular therapy portfolio based on stem cells reprogramming, thereby exhibiting a strong evidence of the understanding future of stem cells reprogramming in the treatment of a broad spectrum of life-threatening diseases.

Table of Contents

1.1 Stem Cells Reprogramming: The Bigger Picture

1.2 Stem Cells Reprogramming: A Promising Revolution

1.3 Research Focus: Stem Cells Reprogramming

1.4 Research Focus: Stem Cells Reprogramming

1.5 Research Scope: Unveiling a Radically Novel Technology

1.6 Analysis Framework: Frost & Sullivan’s Core Value

1.7 Research Methodology: Five Steps toward Success

2.1 Key Elements of Analysis: Stem Cells Reprogramming

2.2 Brief Overview of Stem Cells Reprogramming

2.3 Evolving Stem Cells Reprogramming

2.4 Delivery Methods of Pluripotency Induction

2.5 Molecular Methods of Pluripotency Induction

3.1 Stem Cells Reprogramming Innovations

3.2 Stem Cells Reprogramming Developments

3.3 Stem Cells Reprogramming Advances

3.4 Stem Cells Reprogramming Technologies

3.5 Stem Cells Reprogramming Breakthroughs

3.6 Stem Cells Reprogramming Disruption

3.7 Stem Cells Reprogramming Approaches

3.8 Stem Cells Reprogramming Platforms

3.9 Stem Cells Reprogramming Novelties

3.10 Stem Cells Reprogramming Innovations

4.1 Market Dynamics and Business Opportunities

4.2 Market Forecast by Application

4.3 Market Forecast by Source

4.4 Market Forecast by Sector

4.5 Market Forecast by Technology

4.6 Market Forecast by Region

5.1 Technology Synergy Reshaping the Value Chain

5.2 New Approaches Driving Solutions

5.3 Business Model Hybridization

5.4 Technology and Business Landscape: Accelerators

5.5 Technology and Business Landscape: Challenges

5.6 Technology Transfer Assessment and Perceptions

5.7 Principal Innovators and Patent Holders

6.1 Funding and Investment Models and Adoption

6.2 Funding Trends and Contribution Focus

6.3 Principal Funding Sources

6.4 Funded Programs by Region

6.5 Most Granted Institutions

7.1 Roadmap Tapping into Technology Synergy

7.2 Multicriteria Approach for Benchmarking

7.3 Strategic Portfolio Assessment

7.4 Level 1 Criteria: Innovation Development

7.5 Level 1 Criteria: Financial Performance

7.6 Level 1 Criteria: Market Evolution

7.7 Level 2 Criteria: Key Actions for Success

7.8 Analytic Performance Results

7.9 Multicriteria Final Assessment

7.10 Future Perspective for Stem Cells Reprogramming

8.1 Technology Platforms to Watch

8.2 Strategic Business Cases

8.3 Strategic Business Developments

8.4 Critical Success Factors

9.1 Key Industry Influencers

9.2 Key Industry Models

9.3 Key Industry Participants

9.4 Key Industry References

9.5 Key Industry Exemplars

Legal Disclaimer

Request Sample

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Life Sciences research

13 Jan 2025   |   Global   |   Market Outlook

Top 6 Growth Opportunities for the Digital Health Industry, 2025

Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...

17 Dec 2024   |   Global   |   Market Research

Cybersecurity in Healthcare, United States, 2024

Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...

12 Dec 2024   |   Global   |   Market Outlook

Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...

05 Dec 2024   |   Global   |   Frost Radar

Frost Radar™: Enterprise Conversational AI in Healthcare, 2024

This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-car...

27 Nov 2024   |   Global   |   Market Research

Generative AI in Payer and Provider IT Transformation, Global, 2024-2029

The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts
Related Research
  1. Next-Generation Therapeutic Platforms: AI-Enabled Drug Discovery, Small molecules, Deep Proteomics, RNA Engineering, and Targeted Immunomodulation
    Release Date: 23-Jan-26
  2. Innovations and Growth Opportunities in AI-Driven Drug Discovery, Precision Diagnostics, Advanced Biologics, and Next-generation Vaccines
    Release Date: 17-Jul-26
  3. Recent Advances in Biologics, Regenerative Medicine and Radiotherapies
    Release Date: 19-Sep-25
  4. Novel Therapies for Rare and Genetic Diseases
    Release Date: 29-Jun-18
  5. Innovations and Growth Opportunities in Cell & Gene Therapy, Targeted Protein Degradation, Bacteriophage Therapeutics, and Advanced Drug Delivery
    Release Date: 20-Feb-26

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

Since the advent of stem cells reprogramming after the discovery of the differentiation factors that allow the creation of human induced pluripotent stem cells, researchers all around the world are strongly committed to develop novel methods to design and build human stem cells. Indeed, there is an increasing demand for the more efficient production systems and manufacturing methods of stem cells for potential investigation in disease management. This trend is emphatically envisaged to accelerate the development of both regenerative medicine and drug discovery and development. Moreover, stem cell therapies are acclaimed as the next major advancements in transforming healthcare. Pharmaceutical companies are heavily investing in expanding their cellular therapy portfolio based on stem cells reprogramming, thereby exhibiting a strong evidence of the understanding future of stem cells reprogramming in the treatment of a broad spectrum of life-threatening diseases.
More Information
Deliverable Type Technology Research
No Index No
Podcast No
Author Cecilia Van Cauwenberghe
Industries Healthcare
WIP Number D89C-01-00-00-00
Is Prebook No